Chimes Society

NeuroAiD™1 was first known as a Traditional Chinese Medicine drug marketed in China for approved-indication of cerebral infarction’s functional and neurological deficits, i.e. helping patient recover from their disabilities after a stroke. NeuroAiD™ is marketed outside of CHINA by Moleac Pte Ltd, it is currently available commercially in a number of countries in Southeast Asia and in the Middle East. In research paper NeuroAiD™ is sometimes referred as MLC601 for its brand formulation, or DJ or DPJ which are abbreviations of its Chinese commercial name Danqi Jiaonang

The registration in China was supported by the results obtained from initial double-blind control randomized studies performed in China from 1999 to 2001 on 605 ischemic stroke patients at restoration stage. These studies evidenced NeuroAiD’s efficacy to improve stroke patients’ ability to recover even when started several weeks after the stroke onset. Given its unique profile in attending stroke patients’ needs with a very safe profile, NeuroAiD™ presents a strong opportunity to fill a gap in stroke patients’ treatment in the West.